Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07184983 · ClinicalTrials.gov registry record · NA
RS-tDCS for Cannabis Use Disorder: The C.A.R.E.S. Initiative
A NA study of Cannabis Use Disorder, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- NA
- Development phase
- 46
- Enrollment target
- 1
- Study location
NCT07184983: Recruiting NA study of Cannabis Use Disorder, sponsored by NYU Langone Health.
NCT07184983 is a NA study of Cannabis Use Disorder that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 46 participants, below the 108-participant average among 34 other Cannabis Use Disorder trials with a reported enrollment target (57% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07184983, a NA study of Cannabis Use Disorder, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- NA
- Development phase
- 46 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this sham-controlled pilot randomized controlled trial (RCT) is to evaluate the feasibility, safety, and preliminary efficacy of a one-month intervention consisting of 20 home-based active or sham RS-tDCS sessions paired with audio track guided mindfulness meditation practice in otherwise healthy adults seeking to reduce cannabis use in the context of cannabis use disorder (CUD).
Conditions Studied
Interventions
- BEHAVIORAL Mindfulness meditation
- DEVICE Sham Transcranial Direct Current Stimulation (tDCS)
- DEVICE Active Transcranial Direct Current Stimulation (tDCS)
Study Locations (1)
New York
- NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2025-11-12 |
| Est. Completion | 2027-11-01 |
| Phase | NA |
What NCT07184983 shows while recruiting
NCT07184983 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 108-participant average among 34 other Cannabis Use Disorder trials with a reported enrollment target (57% lower).
The record links to 1 condition, with Cannabis Use Disorder appearing as the primary indexed condition, and to 3 interventions - of which Mindfulness meditation is the first listed.
NCT07184983 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT07184983 about?
NCT07184983 is a clinical study titled "RS-tDCS for Cannabis Use Disorder: The C.A.R.E.S. Initiative". The purpose of this sham-controlled pilot randomized controlled trial (RCT) is to evaluate the feasibility, safety, and preliminary efficacy of a one-month intervention consisting of 20 home-based active or sham RS-tDCS sessions paired with audio track guided mindfulness meditation practice in other...
What is the current status of trial NCT07184983?
This trial is currently recruiting. It is a NA study. The enrollment target is 46 participants. The study started on 2025-11-12. Estimated completion is 2027-11-01.
What conditions does trial NCT07184983 study?
This clinical trial studies the following conditions: Cannabis Use Disorder.
What interventions are being tested in trial NCT07184983?
The interventions under investigation include: Mindfulness meditation (BEHAVIORAL), Sham Transcranial Direct Current Stimulation (tDCS) (DEVICE), Active Transcranial Direct Current Stimulation (tDCS) (DEVICE).
Who is sponsoring clinical trial NCT07184983?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07184983 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cannabis Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07184983's enrollment target sits among peer trials
46 26th of 34 higher than 9 of 34 other Cannabis Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cannabis Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Integrated Treatment for Enhancing Growth in Recovery During Adolescence
RECRUITING · NA
-
Evaluation of a Brief Computerized and Smart Phone-based Intervention for Stress in Regular Cannabis Users
RECRUITING · NA
-
Determining the Effect of Six Weeks of Cannabis Abstinence on Fronto- Striatal fMRI Markers in Adolescents With Cannabis Use Disorder (ABSCAN)
RECRUITING · NA
-
The Neural Underpinnings of Depression and Cannabis Use in Young People Living With HIV
RECRUITING · NA
-
A Brief Intervention for Cannabis Use
RECRUITING · NA
-
Preliminary Efficacy Trial of a Digital Intervention for Depression and Cannabis Use
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI